Dr. Alejandro Madrigal began his medical studies at the Universidad Nacional Autónoma de México (UNAM) and continued his training at the world’s top universities such as University College London (UCL), Stanford, and Harvard. He is currently a Professor of Hematology at UCL and a Professor Emeritus of the National System of Researchers in Mexico. He was an Honorary Affiliated Physician at the Royal Free Hospital (UK) and UCL Cancer Institute. 

He was the founder and first scientific director of the Anthony Nolan Research Institute in London, a leading organization that helps people with blood cancer and/or blood disorders. Through this institution, he has trained hundreds of doctors and scientists and has helped develop multiple cord blood collection centers across the UK.  Hi research primarily revolves around immunotherapy and stem cell transplantation, particularly from unrelated donors. His pioneering work has sought to make this process less complex and more accessible to more people, especially minorities. 

He is a Fellow of the Academy of Medical Sciences and a member of the Royal College of Physicians in the UK. He is also an honorary member of the National Academy of Medicine (Mexico) and the Mexican Academy of Sciences, among many others. In addition, he was president of the European Society for Blood and Marrow Transplantation (EBMT) (2010-2014).

He has received 4 honorary doctorates and was appointed an Officer of the Most Excellent Order of the British Empire (OBE) by Queen Elizabeth II in 2022.

Alejandro Madrigal joined Tecnológico de Monterrey as a Distinguished Professor in Hematology and Cellular Therapy for the School of Medicine and Health Sciences.

• Postdoctoral studies, Harvard University
• Postdoctoral studies, Stanford University
• Doctoral studies, University College London (UCL)
• Medicine and specialty in Internal Medicine, Universidad Nacional Autónoma de México (UNAM)

• Madrigal, J. A., Chávez, M., & Mayani, H. (2022). Advanced Cell Therapy: Beyond the last Frontier in the Treatment of Cancer. A Historical Perspective Emphasizing the Work of Nobel Prize Laureates. Archives Of Medical Research, 53(8), 747-752. https://doi.org/10.1016/j.arcmed.2022.11.006

• Ros-Soto, J., Snowden, J. A., Szydlo, R., Nicholson, E., Madrigal, A., Easdale, S., Potter, M., Ethell, M., & Anthias, C. (2022). Outcomes After Donor Lymphocyte Infusion in Patients With Hematological Malignancies: Donor Characteristics Matter. Transplantation And Cellular Therapy, 28(4), 183.e1-183.e8. https://doi.org/10.1016/j.jtct.2022.01.022

• Petersdorf, E. W., Gooley, T., Volt, F., Kenzey, C., Madrigal, A., McKallor, C., Querol, S., Rafii, H., Rocha, V., Tamouza, R., Chabannon, C., Ruggeri, A., & Gluckman, É. (2020). Use of the HLA-B leader to optimize cord blood transplantation. Haematologica, 106(12), 3107-3114. https://doi.org/10.3324/haematol.2020.264424

• Querol, S., Rubinstein, P., & Madrigal, A. (2021). The wider perspective: cord blood banks and their future prospects. British Journal Of Haematology, 195(4), 507-517. https://doi.org/10.1111/bjh.17468

• Wynn, L. A., & Madrigal, A. (2021). Predictive analytics and cord blood banking: toward utilization-based unit selection. Cytotherapy, 23(7), 641-646. https://doi.org/10.1016/j.jcyt.2021.01.002

More information